S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Vaxxinity Stock Price, News & Analysis (NASDAQ:VAXX)

$0.81
-0.06 (-6.90%)
(As of 12/4/2023 ET)
Compare
Today's Range
$0.72
$0.90
50-Day Range
$0.85
$1.46
52-Week Range
$0.72
$4.47
Volume
477,277 shs
Average Volume
242,219 shs
Market Capitalization
$102.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Vaxxinity MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
764.4% Upside
$7.00 Price Target
Short Interest
Bearish
11.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$51,878 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.58) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

317th out of 952 stocks

Pharmaceutical Preparations Industry

137th out of 434 stocks


VAXX stock logo

About Vaxxinity Stock (NASDAQ:VAXX)

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

VAXX Stock Price History

VAXX Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
See More Headlines
Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/25/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VAXX
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+764.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-75,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$0.49 per share

Miscellaneous

Free Float
51,877,000
Market Cap
$102.64 million
Optionable
Not Optionable
Beta
2.48
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Louis Garfield Reese IV (Age 41)
    Co-Founder & Executive Chairman of the Board
    Comp: $83.28k
  • Ms. Mei Mei Hu J.D. (Age 40)
    CEO & Director
    Comp: $551.73k
  • Dr. Peter Powchik M.D. (Age 66)
    Executive VP, Global Scientific Director and Director
  • Mr. Jason Pesile CPA (Age 50)
    M.B.A., Senior Vice President of Finance & Accounting
  • Ms. Sumita Ray J.D. (Age 49)
    Chief Legal & Administrative Officer
  • Mr. Jon Harrison
    Chief Government Officer
  • Mr. Mark Joinnides MSE
    Chief of Staff
  • Ms. Amy B. Fix M.B.A.
    M.S., R.A.C., Chief Regulatory Officer
  • Dr. Jean-Cosme Dodart Ph.D.
    Senior Vice President of Research
  • Mr. Dario Mirski M.D.
    Senior Vice President of Neuro / Chronic Diseases














VAXX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxxinity stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VAXX shares.
View VAXX analyst ratings
or view top-rated stocks.

What is Vaxxinity's stock price target for 2024?

1 brokers have issued 1 year price targets for Vaxxinity's shares. Their VAXX share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 764.4% from the stock's current price.
View analysts price targets for VAXX
or view top-rated stocks among Wall Street analysts.

How have VAXX shares performed in 2023?

Vaxxinity's stock was trading at $1.40 at the beginning of 2023. Since then, VAXX shares have decreased by 42.2% and is now trading at $0.8098.
View the best growth stocks for 2023 here
.

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our VAXX earnings forecast
.

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) released its earnings results on Wednesday, November, 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04.

What ETF holds Vaxxinity's stock ?

ETFMG Treatments Testing and Advancements ETF holds 35,725 shares of VAXX stock, representing 0.58% of its portfolio.

When did Vaxxinity IPO?

(VAXX) raised $90 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

Who are Vaxxinity's major shareholders?

Vaxxinity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.10%), McAdam LLC (0.05%), New York State Common Retirement Fund (0.02%) and Clarius Group LLC (0.02%). Insiders that own company stock include Lou Reese, Mei Mei Hu, Movers Lab Fund I Lp Prime and United Biomedical Inc.
View institutional ownership trends
.

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VAXX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -